Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formosa 1-Breath Free (NRICM101) in COVID-19 or Influenza-like Symptoms
NCT06175468Phase 3Not yet recruiting
- Sponsor
- China Medical University Hospital
- Start
- Dec 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RespireAid in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by China Medical University Hospital. Primary endpoint: Sore Throat Visual Analogue Scale at 5 days. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
RespireAid
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06175468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175468.